Shows vadadustat meets hematologic efficacy but fails cardiovascular safety noninferiority in non–dialysis-dependent kidney disease, highlighting safety concerns.
Vadadustat, as compared with darbepoetin alfa, met the prespecified noninferiority criterion for hematologic efficacy but not the prespecified noninferiority criterion for cardiovascular safety in patients with NDD-CKD. (Funded by Akebia Therapeutics and Otsuka Pharmaceutical; PRO₂TECT ClinicalTrials.gov numbers, NCT02648347 and NCT02680574.).
No takes yet. Share an insight, caveat, or question.
Chertow et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: